home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

23.02 -0.46 (-1.96%)

Official Closing Price Updated: 7:00 PM EST, Feb 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Hims & Hers Health, Inc. Class A Common Stock

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

49 50 Next >

Hims & Hers Acquires At-Home Lab Testing Facility, Expanding Capabilities to Ultimately Include Affordable Whole Body Testing for Subscribers

February 19, 2025

From Hims & Hers

Via Business Wire

Hims & Hers Earnings Could Be a Game Changer—What to Do Now

February 18, 2025

After a massive 500% run over the past 12 months, shares of Hims & Hers stock might have another trick saved up before earnings announcements.

Via MarketBeat

3 Hot Stocks That Have Already Doubled in 2025 ↗

February 18, 2025

It may be early, but some blazing investments have already delivered wealth-altering gains in this young year.

Via The Motley Fool

Hims & Hers Stock Is On Fire, But Is It a Bubble? ↗

February 18, 2025

The stock isn't as expensive as you might think.

Via The Motley Fool

What Is Driving Hims & Hers Stock Higher? ↗

February 18, 2025

The stock is up 140% this year already.

Via The Motley Fool

Assessing Hims & Hers Health: Insights From 7 Financial Analysts ↗

February 18, 2025

Via Benzinga

Hims & Hers Health Unusual Options Activity For February 10 ↗

February 10, 2025

Via Benzinga

This Moderna Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗

February 18, 2025

Via Benzinga

Coinbase To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

February 18, 2025

Via Benzinga

Hims & Hers: From Viral Ad to Volatile Stock

February 18, 2025

Hims & Hers leverages its viral Super Bowl advertisement and strategic weight loss market entry to achieve stock gains and brand recognition in telehealth.

Via MarketBeat

Hims & Hers Health Stock: A Millionaire-Maker in the Making? ↗

February 18, 2025

The stock has sprinted past $50 per share, after trading at $3 less than two years ago.

Via The Motley Fool

Hims & Hers Stock: More Gains Ahead Or A Pullback? Most Retail Traders Bet On This Path ↗

February 18, 2025

A poll of over 4,000 respondents found that 47% believe the stock will continue its climb past $60, while 44% expect a significant pullback for profit-taking.

Via Stocktwits

Hims & Hers Health Unusual Options Activity ↗

February 07, 2025

Via Benzinga

Novo Nordisk Shares Near New 52-Week Low: Analysts See Big Upside

February 17, 2025

Novo Nordisk shares are closing in on a new 52-week low. Is the stock gearing up for a recovery with sentiment currently low?

Via MarketBeat

Super Micro Computer, Intel, Alibaba And CVS Are Among Top 13 Large-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio? ↗

February 16, 2025

In the last week, these 13 large-cap stocks were top performers. Are they in your portfolio? HIMS, AUR, APP, SMCI, TEM, DKNG, INTC, MNDY, BROS, CVS, BABA, AAPL, ABNB.

Via Benzinga

Stocks Brush Off Global Trade Tensions, PPI Data ↗

February 13, 2025

Stocks are firmly higher today, despite rising global trade tensions and another hotter-than-expected inflation reading.

Via Talk Markets

Topics Economy Stocks / Equities World Trade

Robinhood, Gilead Sciences, Crocs, Lincoln Electric, HubSpot, GE HealthCare And Other Big Stocks Moving Higher On Thursday ↗

February 13, 2025

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

February 12, 2025

Via Benzinga

Why Hims & Hers Terrifies Big Pharma ↗

February 12, 2025

Big pharma tried to stop Hims & Hers' Super Bowl ad.

Via The Motley Fool

GLP-1 Alternatives: 2 Stocks Benefiting From Weight Loss Trends

February 12, 2025

GLP-1 weight loss drugs are in short supply enabling lab to make compounded GLP-1 treatments sold for 80% less than the name-brand drugs.

Via MarketBeat

Why Hims & Hers Health Stock Crushed Novo Nordisk and Viking Therapeutics Today ↗

February 10, 2025

Via The Motley Fool

Super Bowl Commercials 2025: Complete List of Super Bowl LIX Ads And Companies Behind Them ↗

February 10, 2025

The list of Super Bowl LIX commercials and the companies behind the Super Bowl ads.

Via Benzinga

Hims & Hers Takes Aim At Big Pharma In Controversial Super Bowl Ad — Retail Loves The Fight ↗

February 10, 2025

The commercial aired Sunday night on Fox and positioned obesity as "America's deadliest epidemic" while criticizing the $160 billion weight-loss industry and the broader healthcare system.

Via Stocktwits

US Stocks To Open On A Positive Note After A String Of Bad Mondays: Recent Dip Has 'Reached Its Low Point,' Says Technical Analyst ↗

February 10, 2025

U.S. stock futures rose on Monday following Friday's sharp fall as investors digest tariff updates and earnings reports.

Via Benzinga

Topics World Trade

IBD 50 Stock Hims & Hers Faces Backlash Over Provocative Super Bowl Ad ↗

February 07, 2025

Shares rocketed on Friday, but the company might not be out of hot water yet.

Via Investor's Business Daily

EXCLUSIVE: Is Super Bowl $7M Ad Cost Worth It? 61% Say No, 18% Say They Looked Up Companies After Last Year's NFL Championship ↗

February 07, 2025

Benzinga readers pick whether a $7 million Super Bowl cost is worth it for companies and how likely they are to look up a company that may be new to them after the big game.

Via Benzinga

Super Bowl LIX Commercials: AI, Celebs, Muppets, Warren Buffett-Linked Brand Take The Spotlight ↗

February 07, 2025

A list of Super Bowl LIX commercials and the celebrities and athletes attached to star in the ads.

Via Benzinga

Topics Artificial Intelligence

We Asked Retail Traders About Eli Lilly’s Biggest Post-Q4 Risk — Most Say It’s The Weight-Loss Drug Wars ↗

February 07, 2025

Lilly’s fiercest competitor in the obesity market is Novo Nordisk, which offers Ozempic and Wegovy. However, rising threats from other players such as Hims & Hers, Amgen, and Viking Therapeutics also...

Via Stocktwits

Hims & Hers Launches Health Collective and Community Member Council

February 04, 2025

From Hims & Hers

Via Business Wire

Hims & Hers to Announce Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025

February 03, 2025

From Hims & Hers

Via Business Wire

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

49 50 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com